Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for

SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class...